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Abstract  35 
Objective: Acromegaly is characterized by an excess of growth hormone (GH) and insulin 36 
like growth-factor 1 (IGF1), and it is strongly associated with cardiovascular diseases (CVD). 37 
Both acute and long-lasting pro-inflammatory effects have been attributed to IGF1. Previous 38 
results suggest the presence of systemic inflammation in treated patients. Here we assessed 39 
the association between treatment of acromegaly, systemic inflammation and vascular 40 
function.  41 
Design: Ex vivo cytokine production and circulating inflammatory markers were assessed in 42 
peripheral blood from treated and untreated acromegaly patients (N=120), and compared them 43 
with healthy controls. A more comprehensive prospective inflammatory and vascular 44 
assessment was conducted in a subgroup of six treatment-naive patients with follow-up during 45 
treatment.  46 
Results: Circulating concentrations of VCAM1, E-selectin and MMP2 were higher in patients 47 
with uncontrolled disease, whereas the concentrations of IL18 were lower. In stimulated 48 
whole blood, cytokine production was skewed towards a more pro-inflammatory profile in 49 
patients, especially those with untreated disease. Prospective vascular measurements in 50 
untreated patients showed improvement of endothelial function during treatment.  51 
Conclusions: Acromegaly patients are characterized by a pro-inflammatory phenotype, most 52 
pronounced in those with uncontrolled disease. Treatment only partially reverses this pro-53 
inflammatory bias. These findings suggest that systemic inflammation could contribute to the 54 
increased risk of CVD in acromegaly patients.  55 
4  
Introduction 56 
Acromegaly is a rare disease caused by excessive production of growth hormone (GH), 57 
mostly by a pituitary adenoma, and subsequent insulin-like growth factor 1 (IGF1) excess [1]. 58 
GH and IGF1 have numerous immunological, metabolic and cardiovascular effects [2-5]. 59 
Patients with active acromegaly suffer from cardiovascular morbidity and mortality [6, 7]. 60 
Although the mortality risk practically normalizes with adequate treatment, cardiovascular 61 
disease (CVD) risk factors often persist [8]. The mechanism underlying this phenomenon is 62 
not well understood; direct deleterious effects of GH and IGF1 on the cardiovascular and/or 63 
immune system have been suggested [9], but prospective systematic analyses are lacking.  64 
Atherosclerosis is the main pathophysiological process driving CVD, and is characterized by 65 
subclinical systemic inflammation and inflammatory arterial wall changes [10], in which 66 
immune cells play a pivotal role. Recently, the CANTOS and COLCOT trials provided proof-67 
of-principle that targeting low-grade inflammation reduces cardiovascular events in high-risk 68 
patients [10, 11].  69 
Given the high prevalence of cardiovascular disturbances in acromegaly patients, and the 70 
previously suggested pro-inflammatory effects of GH and IGF-1, we hypothesized that 71 
subclinical inflammation is present in acromegaly patients, which contributes to their CVD 72 
risk. In a cross-sectional study in treated acromegaly patients and healthy controls [12], we 73 
identified a pro-inflammatory phenotype and endothelial dysfunction in patients despite 74 
treatment. Building on this, we now hypothesize that treatment-naive acromegaly patients 75 
display an even more pronounced pro-inflammatory phenotype, which is only partly 76 
normalized by acromegaly treatment. We extended our cross-sectional cohort, and 77 
prospectively followed treatment-naive patients during treatment, in order to detail the effect 78 
of treatment on the inflammatory and vascular phenotype that we found previously.  79 
 80 
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Materials and Methods 81 
This study was conducted in two academic referral centers (Radboud University Medical 82 
Center (Radboudumc), Nijmegen, the Netherlands, and the Cluj County Emergency Hospital 83 
in Cluj-Napoca, Romania).  84 
  85 
Subjects 86 
For the cross-sectional part, we included 44 treated (N=38) and treatment-naive (N=6) 87 
acromegaly patients that were admitted to the Cluj County Emergency Hospital (Cluj-Napoca, 88 
Romania) and nine healthy controls from this area, together with 71 treated patients from the 89 
Radboudumc and 41 healthy controls, who were described in our previous study [12]. 90 
For the prospective part, we included six additional treatment-naive patients from the 91 
Radboudumc, and six sex- and age-matched healthy controls for comparison at baseline 92 
(Table 1; Figure 1).  93 
 94 
Subjects with inflammatory comorbidities, active malignancies or those using systemic 95 
immunosuppressive medication were excluded. In addition, patients with inadequately treated 96 
hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), 97 
poorly controlled diabetes mellitus (HbA1c >69 mmol/mol for >1 year), ischemic CVD, or an 98 
alcohol intake of >21 IU per week were excluded.  99 
The above-mentioned exclusion criteria also applied to controls. In addition, controls with 100 
pituitary hormone disturbances were excluded.  101 
All patients had a history of biochemically and radiologically confirmed active acromegaly, 102 
defined as an increased serum IGF1 level (>2 SD above the mean corrected for sex and age) 103 
and insufficient suppression of serum GH levels (≥0.4 µg/L in Nijmegen, ≥1 µg/L in Cluj-104 
Napoca) during an oral glucose tolerance test (OGTT) [1], combined with the presence of a 105 
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pituitary adenoma on a MRI- or CT-scan.  106 
After diagnosis, standard care was pre-treatment with a long-acting somatostatin receptor 107 
analogue (SSA) for 6 months, followed by endoscopic endonasal transsphenoidal 108 
adenomectomy (EETA), or primary medical therapy in patients who were not suitable for 109 
surgery. If biochemical control was not obtained by SSA monotherapy, the GH-receptor 110 
antagonist Pegvisomant (PEGV) or a dopamine-agonist was added. In case of recurrent or 111 
residual disease after surgery, medical therapy was (re)started. When possible, patients 112 
underwent a second surgical approach. Patients with uncontrolled disease despite surgery 113 
and/or maximal tolerable medical therapy underwent radiotherapy.  114 
Surgical control was defined as postoperative IGF1 levels within the sex- and age-adjusted 115 
reference range, preferably combined with a sufficient suppression of serum GH levels (GH 116 
≤0.4 µg/L) during an oGTT, performed approximately four months after surgery, without use 117 
of GH- or IGF1-lowering drugs. Biochemical control was defined as IGF1 levels within the 118 
sex- and age-adjusted reference range with use of GH- or IGF1-lowering drugs [13].  119 
Surgically and biochemically controlled patients are both considered controlled. 120 
Patients with active acromegaly (e.g. IGF1 levels above the reference range) despite treatment 121 
are uncontrolled. Both controlled and uncontrolled patients are considered treated. 122 
Postmenopausal women had gonadotrophin levels were in the postmenopausal range and/or 123 
were they older than 55 years. Hypogonadism was defined as estrogen- or total testosterone 124 
levels below the reference range in premenopausal women and men, adrenal insufficiency 125 
(AI) as a serum morning cortisol <100 nmol/L, after withdrawal of glucocorticoids for 24 h, 126 
or a maximal cortisol response ≤550 nmol/L during an insulin tolerance test or a 250 μg 127 
ACTH (Synacthen) stimulation test [14], hypothyroidism as free thyroxin plasma levels 128 
<8 pmol/L (reference range 8–22 pmol/L), hypopituitarism as the presence of one or more of 129 
the aforementioned pituitary hormonal deficiencies, hypertension as use of antihypertensive 130 
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therapy based on a previous diagnosis of hypertension or at least three measurements of a 131 
systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg on different 132 
days, and diabetes mellitus (DM) as use of glucose-lowering medication based on a previous 133 
diagnosis of DM or fasting glucose levels ≥7 mmol/L and/or random glucose levels ≥11.1 134 
mmol/L at distinct timepoints.  135 
The study was conducted in accordance with the Declaration of Helsinki and approved by our 136 
local ethical committee (CMO regio Arnhem-Nijmegen; 2015-2023). All subjects signed 137 
informed consent prior to participation. 138 
 139 
Study protocol 140 
Anthropometric measurements 141 
Blood pressure and heart rate were measured in supine position on both arms after 10 minutes 142 
of rest. Height, weight, waist, and hip circumference were determined between 0830 and 1030 143 
h. Measurements were performed by one experienced non-blinded investigator per center. 144 
 145 
Circulating inflammatory and cardiovascular markers 146 
Blood was drawn from the brachial vein in a fasted state, in 10 mL EDTA tubes (Vacutainer, 147 
BD; Franklin Lakes, NJ, USA). Within 3 hours, tubes were centrifuged (3800 RPM, 10 148 
minutes, room temperature), and plasma was collected and stored at −80°C until assayed. 149 
Plasma IGF1 levels were determined by a chemiluminescent immunometric assay (Liaison, 150 
DiaSorin, Saluggia, Italy) in Nijmegen and by a Cobas e 411 immunoassay analyzer (Roche 151 
Diagnostics, Basel, Switzerland) in Cluj-Napoca. Lipid levels were measured on a Cobas 152 
8000 analyzer (Roche) in Nijmegen and an AU 680 spectrophotometer (Beckman Coulter, 153 
Brea, California, USA) in Cluj-Napoca. LDL cholesterol levels were calculated using the 154 
Friedewald formula. 155 
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Plasma levels of E-Selectin, Matrix Metalloproteinase (MMP)2, vascular cell adhesion 156 
molecule (VCAM)1, high sensitivity C-Reactive Protein (hsCRP), and interleukin (IL)18 157 
were measured with DuoSet enzyme-linked immunosorbent assays (ELISA; R&D Systems, 158 
Abingdon, United Kingdom), with a sensitivity of 93.8 pg/mL (E-Selectin), 625 pg/mL 159 
(MMP2), 15.6 pg/mL (VCAM1, hsCRP), and 7.8 pg/mL (IL18). IL18 binding protein 160 
(IL18BP) was measured with a high sensitivity Quantikine ELISA assays (R&D; sensitivity 161 
2.25 pg/mL).  162 
 163 
Ex-vivo stimulation of whole blood (WB) 164 
E. coli lipopolysaccharide (LPS; serotype 055: B5) was purchased from Sigma-Aldrich (St. 165 
Louis, MO, USA) and re-purified as previously described [15]. Phytohemagglutinin (PHA) 166 
was purchased from Sigma-Aldrich (PHA-P; L1668). Candida albicans (C. albicans) ATCC 167 
MYA-3573 (UC 820) and Staphylococcus aureus (S. aureus) Rosenbach ATCC 25923 were 168 
grown overnight in Sabouraud and Brain Heart Infusion broth at 37°C, respectively, and 169 
harvested by centrifugation, washed twice, and resuspended in Roswell Park Memorial 170 
Institute (RPMI) 1640 culture medium (Dutch Modification, Gibco, Thermo Scientific, 171 
Waltham, MA, USA)[16]. C. albicans yeasts were heat-killed for 30 minutes at 95°C.  172 
Blood was drawn from the brachial vein in a fasted state, between 0800 and 1000 h, in 4 mL 173 
lithium-heparin tubes (Vacutainer). Within three hours, 100 μL of WB was incubated at 37°C 174 
with 400 μL of stimulus (LPS 100 ng/mL, PHA 10 µg/mL, C. albicans 1x106/mL, S. aureus 175 
1x106/mL) or RPMI (unstimulated condition) per well. After 48 hours, supernatants were 176 
collected and stored at −20°C until assayed.  177 
Cytokine concentrations were measured in supernatants by commercial ELISA kits according 178 
to the manufacturer’s instructions: tumor necrosis factor alpha (TNFa), IL1B, IL1 receptor 179 
antagonist (IL1Ra), IL6 (DuoSet, R&D) with a sensitivity of 3.9 pg/mL (IL1, 4.7 pg/mL 180 
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(IL6), 7.8 pg/mL (TNFa), and 39.0 pg/mL (IL1Ra). Interferon gamma (IFNg) was measured 181 
using a PeliKine Compact kit (Sanquin; Amsterdam, sensitivity 3.9 pg/mL). For the existing 182 
cohort, IL10 was measured using a PeliKine kit (sensitivity 2.34 pg/mL), for the untreated 183 
patients, their controls and the Cluj cohort, using a kit from R&D (sensitivity 11.7 pg/mL).  184 
 185 
Plasma and WB ELISAs were performed in three batches (existing cohort, Cluj-Napoca 186 
cohort and prospective cohort) without previous freeze-thaw cycles. Control samples from the 187 
same batch were used to evaluate the comparability between the three WB batches.  188 
 189 
Cell counts 190 
Cell counts were obtained in fresh EDTA blood with a Sysmex automated hematology 191 
analyzer (XN-450; Sysmex Corporation, Kobe, Japan). In Cluj-Napoca, cell counts were 192 
obtained using an automated Mindray spectrophotometer (BC-6200; Shenzhen Mindray Bio-193 
Medical Electronics Co., Ltd., Shenzhen, China). 194 
Prospective analyses 195 
Six treatment-naive newly-diagnosed patients were studied at their first visit (T0), after 6 196 
months (T1) and after 15 months (T2) in the Radboudumc. At each visit, venous blood was 197 
drawn in the fasted state, and anthropometric and vascular measurements were performed. 198 
Between T0 and T1, patients were pretreated according to the abovementioned protocol. Just 199 
after T1, patients underwent EETA.  200 
 201 
Flow cytometry 202 
Monocyte subpopulations were identified with flow cytometry using the lysis-no-wash 203 
strategy (BD Pharm Lyse lysing buffer, Becton Dickinson) on fresh EDTA blood. 100µl of 204 
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blood was stained by monoclonal antibodies (CD16 FITC NKP15 Becton & Dickinson, and 205 
CD14 PE RMO52, HLA-DR Immu357 PC5.5, CD45 PC7 J33; last three Beckman Coulter). 206 
Surface expression was assessed using FC500 and CytoFLEX flow cytometer and analyzed 207 
with Kaluza software version 2.1 (Beckman Coulter). The applied gating strategy was in 208 
short; monocytes were selected in the SSC/CD45+ plot, gated to SSC/HLA-DR+ plot, 209 
identifying monocytes as CD45+ HLA-DR+ cells with monocyte scatter properties. Exclusion 210 
of lymphocytes and natural killer cells was performed by excluding CD45+ HLA-DR+ CD14- 211 
CD16- cells. In the CD14/CD16 plot, the percentages of gated monocyte subsets (classical 212 
(CD14++CD16−), intermediate (CD14++CD16+), non-classical monocytes 213 
(CD14+CD16++)) were used for analyses. Identification of monocytes subsets followed 214 
current recommendations [17]. 215 
 216 
RNA isolation 217 
PBMCs were isolated using Ficoll-Paque PLUS (GE Healthcare Biosciences). After isolation, 218 
the monocyte fraction was increased with hyperosmotic Percoll gradient isolation (Sigma). 219 
Percoll-isolated monocytes stored at baseline were isolated using a TRiZOL/RNeasy hybrid 220 
protocol. In short, per 1 mL of TRiZOL 200 µL of chloroform was added, mixed, incubated at 221 
room temperature for 5 min and spun down for 15 min (12000g) at 4°C. The upper aqueous 222 
phase was transferred to a RNA-se free Eppendorf tube, and an equal volume of 70% ethanol 223 
was added. After thorough mixing, the sample was loaded unto RNeasy mini columns (Qiagen), 224 
after which the manufacturers protocol was followed. After the last manufacturer’s step, 15 µL 225 
of RNase free water was added, incubated for 5 min, and spun down.  226 
 227 
RNA sequencing and differential gene expression analysis 228 
The RNA concentration was determined on the Qubit; the quality using Nanodrop technology. 229 
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Library preparation was performed using the Quantseq 3‘mRNA-Seq Library Prep Kit-FWD 230 
(Cat#015.96, Lexogen) according to the manufacturer’s protocol. RNA input was normalized 231 
to 150 ng. All samples were processed in a single library preparation. After quality control of 232 
each library (using Qubit and tapestation), libraries were pooled and diluted to 4 nM. Thereafter, 233 
libraries were sequenced in one round on a NextSeq 500 (Illumina) with a 1.4 pM final loading 234 
concentration. 235 
Low quality filtering and adapter trimming was performed using Trim Galore!, V0.4.4_dev 9, 236 
a wrapper tool around the tools Cutadapt v1.18 and FastQC v0.11.5 (Babraham 237 
Bioinformatics). Reads were mapped to a human reference genome (GRCh38.95, Ensembl) 238 
with Star v2.6.0a [18] resulting in BAM. These BAM files were counted (number of reads 239 
mapped to a feature, e.g. a gene) with HTSeq (HTSeq-count tool v0.11.0 [19]) using 240 
a complementary .gtf file, containing annotation for GRCh38.95 (Ensembl). MultiQC was 241 
used to combine results and quality checks of all samples[20]. Total reads were between 14-242 
17 million, of which percentage uniquely assigned reads were between 52-61%, aligned reads 243 
between 79-83%. LogFold shrinkage was performed with apeglm for easier comparison 244 
between groups [21]. Differential gene expression analysis was carried out with DESeq2 245 
v1.22.0 in R[22], with internal statistical and normalization method (i.e. adjustment of P-246 
value for multiple testing with Benjamini–Hochberg). The average expression of patients 247 
versus controls was tested, with correction for sex.   248 
 249 
Vascular measurements 250 
Subjects refrained from exercise and consumption of caffeine, alcohol, dark chocolate, 251 
vitamin C-rich products and vitamin supplements for 24 hours and fasted for at least six 252 
hours. Vascular measurements were performed in a supine position after at least 15 minutes of 253 




Pulse wave velocity and pulse wave analysis  257 
Pulse wave velocity (PWV) and pulse wave analysis (PWA) were performed with a 258 
SphygmoCor EM3 tonometry device (AtCor Medical, Sydney, Australia) by a single 259 
investigator according to the manufacturer’s instructions. 260 
Heart Rate Corrected Central Augmented Pressure was calculated based on the median of 3 261 
PWA measurements of the right radial artery. PWV was calculated as 80% of the direct 262 
distance between the palpation site of the right common carotid to the right femoral artery 263 
divided by the pulse transit time[24].  264 
 265 
Ultrasound measurements 266 
Ultrasound measurements were performed by a single technician on a Terason t3000 267 
ultrasound device (Aloka, UK), and analyzed by a single observer using computer-assisted 268 
analysis with edge-detection and wall-tracking software (DICOM Encoder Analysis 269 
Combo)[25]. 270 
 271 
Flow-mediated dilation (FMD) 272 
FMD (% diameter change: (peak diameter – baseline diameter)/baseline diameter) was 273 
measured in the distal third of the brachial artery of the right arm using high-resolution B-274 
mode 10 MHz ultrasonography and simultaneous acquisition of pulsed-wave Doppler velocity 275 
signals according to a validated protocol [23]. 276 
 277 
Nitroglycerine-mediated dilation (NMD) 278 
One minute prior, and ten minutes after 0.4 mg nitroglycerine sublingually, brachial artery 279 
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diameter and blood flow velocity were measured and analyzed following above-mentioned 280 
FMD analysis protocol.  281 
 282 
Intima-media thickness (IMT)  283 
IMT was measured using high-resolution B-mode 10 MHz ultrasonography in the common 284 
carotid artery on the far wall, at three different angles [26, 27]. IMT was identified as the 285 
region between the lumen-intima border and the media-adventitia border. Regions of interest 286 
were manually marked and at least 50 frames per scan were analyzed to gain a representative 287 
mean of lumen diameter and IMT. Analyses were randomly repeated in order to retain 288 
accuracy. Mean IMT was calculated from at least 40 useful frames at three different angles. 289 
 290 
Statistical analysis 291 
Data were analyzed with SPSS 25.0. Data are presented as unadjusted means with SD or 292 
medians with minimum and maximum values for continuous variables, depending on the 293 
normality of the distribution as determined by the Shapiro-Wilk test. Differences between 294 
patients and controls were tested with an independent samples T-test or a Mann-Whitney U-295 
test (depending on the normality of the distribution) for continuous parameters and with the 296 
Fisher Exact test in case of categorical data. Data on cytokines and circulating parameters was 297 
log-transformed prior to analysis with ANCOVA; BMI and leukocyte count were associated 298 
with cytokine production and circulating parameters, and were included as covariates. For 299 
leukocyte counts, BMI and age were used as covariates. Since leukocyte counts were not 300 
measured in nine controls of the Cluj cohort (5.1% of total cases), these values were 301 
considered missing at random, and were imputed based on subject characteristics (age, sex, 302 
IGF1 concentration, group (control/patient)) and leukocyte counts obtained in other controls 303 
using multiple imputation (5x) to be able to use leukocyte count as a covariate. 304 
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Since cytokine concentrations were measured in three batches, we included batch number as a 305 
fixed factor in our ANCOVA model. Since concentrations of other circulating inflammatory 306 
factors were not significantly influenced by batch, batch was only included as a covariate in 307 
analyses on IL18BP concentrations. We also included DM type 2 as a covariate, which turned 308 
out to be a significant covariate only for VCAM1, but did not influence our outcomes. 309 
Correlations were determined on non-transformed data using Spearman rank correlation. All 310 
tests were two-tailed. P-values of <0.05 were considered statistically significant.  311 
 312 
For the prospective part, results were plotted using Graphpad Prism. Due to the small number 313 
of subjects (N=6), statistical analysis was not expedient given the low power. The results of the 314 
prospective part are therefore depicted in a descriptive manner, and used to explore and 315 
validate the associations that were observed in the cross-sectional study. 316 
 317 
Results 318 
Subject characteristics  319 
Of the 121 patients, 34 (28.1%) were cured, 40 (33.1%) were biochemically controlled, and 320 
35 (28.9%) were uncontrolled. 12 (9.9%) patients were treatment-naive. DM type 2 was more 321 
prevalent in treated patients compared to untreated patients and controls (P=0.001), but 322 
HbA1c levels did not differ significantly between the patient groups (Table 1).  323 
 324 
Prospective subgroup characteristics  325 
Five patients were pretreated with medical therapy for 6 months, followed by EETA (Table 326 
2). One patient refused pretreatment and underwent EETA three months after diagnosis and 327 
consequently did not undergo measurements at T1.  328 
 329 
15  
IGF1 levels 330 
There was no difference between the mean plasma IGF1 levels in controlled patients 331 
(17.8±4.5 nmol/L) and controls (19.3±6.15 nmol/L). Untreated patients had higher IGF1 332 
levels (68.2±11.5 nmol/L) than uncontrolled patients (38.7±18.6 nmol/L; P<0.001), and those 333 
two groups had higher IGF-1 levels than controls and controlled patients (P<0.001). IGF1 334 
levels decreased during treatment in all 6 patients that were prospectively followed during 335 
treatment. 336 
 337 
Peripheral blood cell composition  338 
In patients, platelet (242 (124-381) vs. 271 (154-419) ×109/L; P=0.036) and leukocyte (5.63 339 
(3.36-12.06) vs. 6.51 (3.39-11.62) ×109/L; P=0.002) counts were lower compared to controls. 340 
The lowest leukocyte counts were found in controlled patients (5.43×109/L (3.36-12.06); 341 
Figure 2C). Leukocyte counts correlated negatively with IGF1 levels (R-0.334; P=0.022) in 342 
controls, and positively in patients (R 0.287; P=0.001). 343 
Leukocyte counts tended to be lower in untreated patients compared to the total group of 344 
controls (Figure 2C), but did not evidently change during SSA treatment (Figure 2D), nor did 345 
platelet counts.  346 
 347 
Ex vivo anti-inflammatory cytokine production  348 
The production of TNFa, IL6, IL1, IL1Ra and IFNg did not differ between patients and 349 
controls, nor between the patient subgroups.  350 
In line with our previous study, stimulated anti-inflammatory IL10 production was higher in 351 
controls compared to controlled patients (P=0.01 for PHA; P=0.06 for LPS; Supplementary 352 
Table A.1). IL10 production tended to be higher in controlled patients compared to untreated 353 
and uncontrolled patients, although these differences were not statistically significant. 354 
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Prospectively, LPS-induced IL10 production increased during treatment with SSA in all but 355 
one patient, thereafter they decreased again, resulting in slightly higher IL10 production at T2 356 
compared to T0 (Figure 2). 357 
 358 
IGF1 concentrations positively correlated with IL6 (R 0.3; P=0.001) and IL1Ra (R 0.3; 359 
P<0.001) production in patients, but not in controls. There was a tendency towards a negative 360 
correlation between IGF1 concentrations and LPS-induced IL10 production (R-0.169; 361 
P=0.06) in patients.  362 
 363 
Circulating markers of (vascular) inflammation  364 
The circulating levels of the endothelial dysfunction marker VCAM1 were highest in 365 
untreated patients compared to controls and controlled patients (both P<0.001), and compared 366 
to uncontrolled patients (P=0.024). Also, in uncontrolled patients, VCAM1 levels were 367 
higher compared to controls (P=0.011) and controlled patients (P<0.001). Likewise, E-368 
selectin levels were higher in patients compared to controls (P=0.03); the highest levels were 369 
found in uncontrolled patients (P=0.02) compared to controls; the same trend was observed 370 
for untreated patients compared to controls (P=0.06). Levels were comparable between 371 
controls and controlled patients (Figure 3; Supplementary Table A.1). 372 
 373 
MMP2 concentrations were comparable in controls and treated patients. However, they were 374 
higher in untreated patients compared to uncontrolled patients (P=0.02), and even more 375 
pronounced compared to controls and controlled patients (P<0.001). In uncontrolled patients, 376 
MMP2 concentrations were also higher compared to controlled patients (P<0.001) (Figure 3). 377 
hsCRP concentrations were lower in untreated patients compared to the other three subgroups 378 
(P<0.001), whereas they were comparable in treated patients and controls (Figure 4; 379 
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Supplementary Table A.1). 380 
 381 
IL18BP concentrations differed between the groups (P<0.001), and were lowest in controls. 382 
Controlled and untreated patients had higher levels than controls (both P<0.001; Figure 4). 383 
Untreated patients had higher IL18BP levels than all other groups (P<0.001). IL18 384 
concentrations were higher in controls compared to patients (P=0.004); the lowest 385 
concentrations were found in uncontrolled patients (P=0.02 compared to controls; Figure 4).  386 
Patients had a lower IL18/IL18BP ratio than controls (P=0.04), although differences between 387 
the patient subgroups were not statistically significant.  388 
 389 
In controls, IGF1 and IL18BP concentrations were positively correlated (R 0.43; P=0.001), 390 
whereas IGF1 concentrations and IL18/IL18BP ratio correlated negatively (R -0.45; 391 
P=0.001). In addition, IGF1 concentrations showed a positive correlation with VCAM1 (R 392 
0.38; P=0.003), and a trend towards a negative correlation with hsCRP concentrations (R -393 
0.22; P=0.09). In patients, IGF1 concentrations correlated positively with IL18BP 394 
concentrations (R 0.4; P<0.001), and negatively with IL18/IL18BP ratio (R -0.4; P<0.001). In 395 
addition, IGF1 correlated strongly with MMP2 (R 0.34; P<0.001), VCAM1 (R 0.49; 396 
P<0.001) and E-selectin concentrations (R 0.31; P<0.001), and negatively with hsCRP 397 
concentrations (R -0.18; P=0.046).  398 
 399 
During treatment, circulating IL18 concentrations increased, the highest levels were measured 400 
at T1. This was paralleled by a mild increase in IL18BP levels at T1, whereas levels at T0 and 401 
T2 were comparable. hsCRP concentrations increased in all prospectively followed patients, 402 
except for the uncontrolled female patient (no.3), although her hsCRP concentration increased 403 
during SSA treatment (Figure 4). MMP2 and VCAM1 concentrations decreased in all patients 404 
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except patient no.3. E-selectin concentrations did not change (Figure 3).  405 
 406 
Prospective analysis of monocyte subtypes  407 
Flow cytometry revealed a trend towards a shift of monocyte subtypes during treatment, with 408 
an increase in nonclassical monocytes from T0 to T2 (P=0.09). At baseline, nonclassical 409 
numbers were lower in 5 out of 6 patients than their controls, but this was not significant.   410 
 411 
The monocyte transcriptome of treatment-naive patients  412 
We performed RNA sequencing on Percoll-isolated monocytes from the untreated patients 413 
and their controls. Using a cut-off of False Discovery Rate (FDR)<0.05 and log(2) fold 414 
change of >1.5 or <-1.5, no genes were differentially expressed. To increase sensitivity to 415 
detect potentially relevant transcriptomic changes, we explored additional signals with an 416 
FDR<0.05 and log(2)fold change of >0.5 or <-0.5 (Appendix A-Supplementary Table A.2). 417 
The PCA (Principal component analysis) plot (Appendix A-Supplementary Figure A.1) 418 
indicates that the separation between patients and controls was more distinct for women than 419 
men; the top up- and downregulated genes for female patients and controls are depicted in 420 
Appendix A-Supplementary Table A.3. 421 
 422 
Several of the upregulated genes in patients are linked to inflammation or metabolic 423 
regulation. The top upregulated gene, pyruvate dehydrogenase kinase 4 (PDK4), is pivotal in 424 
M1 macrophage polarization, in which PDK2/4 deficiency prevented production of pro-425 
inflammatory cytokines normally induced by treating macrophages with LPS + IFNg [28]. 426 
Also ERAP2, a central factor for peptide trimming in the generation of most HLA class I-427 
binding peptides, was among the list, as were LILRA5 (a selective inductor of pro-428 
inflammatory cytokine production), PRKAG1 (encoding a regulatory subunit of the AMP-429 
activated protein kinase (AMPK), important in regulating cellular energy demands in states of 430 
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cellular stress), and LGALS9, encoding galectin-9, an important controller of AMPK. The 431 
HIF-1a target gene DDIT4 and ADGRG1, an adhesion GPCR restricted to cytotoxic 432 
lymphocyte/NK cells, were among the downregulated genes.  433 
 434 
Prospective vascular measurements  435 
PWV and PWA did not change over time (Figure 5). IMT however, decreased in all but one 436 
patient. At T1, FMD had increased in all 5 patients (one patient skipped T1), compared to T0. 437 
At T2, FMD had improved in 4 out of 6 patients compared to T0 (Figure 6). Interestingly, 438 
baseline diameter decreased in all but one patient, whereas FMD peak diameter increased in 439 
all patients compared to T0. 440 
 441 
Discussion 442 
In this study, we show that acromegaly patients display an altered, complex immunological 443 
fingerprint and signs of endothelial damage, which is only partially normalized by disease-444 
specific treatment. By prospectively following a subset of treatment-naive patients, we further 445 
examined the effects of treatment on inflammatory markers and vascular changes at an 446 
individual level.  447 
 448 
In a previous study, we showed that ex vivo cytokine production (IL1B, IL1Ra, IFNg) in 449 
(uncontrolled) acromegaly patients differed from healthy controls, indicative of an altered 450 
behavior of immune cells, and that circulating markers suggest vascular inflammation in 451 
acromegaly patients [12]. Importantly, at a cellular level, anti-inflammatory and 452 
atheroprotective IL10 production was decreased in both controlled and uncontrolled patients. 453 
Since this study included few uncontrolled patients and no untreated patients, we included 454 
additional uncontrolled and untreated patients to form the present cohort, which confirmed the 455 
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defective production of IL10 in controlled patients compared to controls, and also (trending) 456 
in uncontrolled and untreated patients. In addition, IGF1 concentrations negatively correlated 457 
with ex vivo IL-10 production, and IL10 production modestly increased during SSA 458 
treatment. However, we did not reproduce the earlier observed increased IL1B, IL1Ra and 459 
IFNg production in uncontrolled patients compared to controls, and therefore cannot further 460 
elucidate the role of those proinflammatory cytokines in modulation of cardiovascular risk in 461 
acromegaly patients.  462 
Importantly, we also found lower numbers of nonclassical monocytes, which are anti-463 
inflammatory and mainly involved in tissue repair and vascular homeostasis [29], in 5 out of 6 464 
treatment-naïve patients compared to their controls; these numbers increased during 465 
treatment. Last, by using a less stringent cut-off order to increase the sensitivity of our 466 
transcriptome analysis, we identified several genes (e.g. PDK4, ERAP2, LILRA5; 467 
Supplementary Table A.3) linked to inflammation or metabolic regulation to be upregulated 468 
in patients. Importantly, these latter data need further validation. 469 
Together, these findings imply pro-inflammatory changes at the level of the immune cell in 470 
acromegaly.   471 
 472 
The differences in circulating markers of (vascular) inflammation between patients and 473 
healthy controls are even more pronounced. In accordance with previous reports [30-33], the 474 
classical inflammatory marker hsCRP was significantly lower in untreated patients compared 475 
to controls and treated patients, and increased after initiation of treatment, which is not always 476 
accompanied by a less inflammatory phenotype. Interestingly, IL18 concentrations increased 477 
during treatment, but remained lower than the concentrations observed in controls, which 478 
corresponds with the lower IL18 concentrations and IL18/IL18BP ratio we observed earlier in 479 
controlled patients. Compared to controls, levels of the markers of endothelial damage E-480 
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selectin and VCAM1 were higher in uncontrolled and untreated patients, and comparable in 481 
controlled patients; this was not observed previously, although others have reported higher 482 
VCAM1 concentrations in active acromegaly patients compared to controls [30, 34]. Further 483 
suggesting causality of IGF-1/GH excess in endothelial damage is the observation that 484 
VCAM1 concentrations decreased during treatment and correlated with IGF1 concentrations.  485 
Last, we observed higher concentrations of MMP2, which is associated with plaque 486 
destabilization [35], in uncontrolled and untreated patients, and MMP2 concentrations 487 
correlated with IGF1 levels and decreased during treatment, again suggesting a role for IGF1. 488 
To conclude, we found biochemical evidence for endothelial dysfunction and plaque 489 
destabilization in acromegaly patients, which respond to treatment and normalize in those 490 
with controlled disease.  491 
The observation that levels of circulating inflammatory markers did not normalize in the 492 
patient with persistently uncontrolled disease during follow-up supports this conclusion.  493 
 494 
The decline in concentrations of circulating inflammatory markers and pro-inflammatory 495 
cytokine production, and the increase of IL10 production at T1, might be caused by the 496 
combined effects of (partial) disease control and SSA treatment. At T2 we observed slightly 497 
higher levels of pro-inflammatory markers compared to T1, which was not explained by 498 
residual disease activity as those patients had controlled disease, but might be explained by 499 
the cessation of SSAs and therefore absence of their suggested anti-inflammatory effects [36-500 
38].  501 
 502 
Endothelial dysfunction is considered the earliest stage of atherosclerotic disease [39], and has 503 
been reported in acromegaly patients [6, 7, 9, 40]. In the prospectively followed treatment-504 
naive patients, we likewise found improvement of FMD during treatment, which implies 505 
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improvement in endothelial function. Interestingly, FMD was higher in most patients at T1 506 
compared to T2, which might be a SSA-related effect, since SSA are reported to beneficially 507 
influence endothelial function and arterial stiffness [41]. IMT decreased during treatment in 508 
all but one patient, whereas PWV and PWA (all surrogate markers for more advanced stages 509 
of atherosclerosis) remained stable; the latter may be partially explained by the stable blood 510 
pressure that was observed during treatment, as these measures are strongly linked to blood 511 
pressure [42]. These findings correspond with earlier reports [43, 44].  512 
 513 
This study has some limitations. The major limitation is our small size of the prospective 514 
subgroup. Therefore, we used a qualitative and descriptive approach in reporting the study 515 
outcomes, and these findings need further validation. While correcting for ethnicity and the 516 
presence of DM type 2 did not significantly influence our results, we cannot completely 517 
exclude their influence. Last, although most studies suggest that the effects of IGF1 on 518 
cardiovascular and inflammatory homeostasis predominate in GH/IGF1 excess [45, 46], we 519 
did not assess the independent effects of GH. In our cohort, two patients were suffering from 520 
a GH deficiency; both received adequate GH suppletion therapy. GH deficiency is known to 521 
induce a pro-inflammatory state, which is reversed by adequate GH suppletion [47, 48] so we 522 
consider it unlikely that the adequately corrected GH deficiency of those two patients did 523 
influence our results. 524 
 Importantly, since we extended our existing cohort by pooling data, the conclusions of the 525 
current study are likely related to those of the previous study. 526 
Although controls were younger than patients, and had less comorbidities, we did not find 527 
large differences in cardiovascular and inflammatory markers between controls and controlled 528 
patients, which highlights the importance of stringent disease control. 529 
 530 
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To conclude, acromegaly induces a complex inflammatory footprint, which is mostly, but not 531 
exclusively, pro-inflammatory. Reduced cellular production of anti-inflammatory IL10, 532 
coincides with elevated levels of markers of endothelial dysfunction and MMP2, while hsCRP 533 
and IL18 levels are lower in patients. In treatment-naive patients, our findings suggest a shift 534 
in monocyte subpopulations with a smaller anti-inflammatory subset. While ex vivo cytokine 535 
production capacity is only partly restored after disease control, circulating inflammatory 536 
markers return to normal, and endothelial dysfunction declines. Since both inflammation and 537 
endothelial dysfunction promote atherogenesis, these findings underscore the importance of 538 
timely and aggressive treatment in order to prevent CVD.   539 
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Table 1. Clinical characteristics in patients and controls. Values are displayed as mean with 759 
SD (standard deviation) or as median with minimum and maximum, depending on the 760 
normality of the distribution. Categorical variables are displayed as numbers. BMI: body 761 
mass index in kg/m2; BP: blood pressure; RT: radiotherapy; SSA: Somatostatin analogue; 762 
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PEGV: Pegvisomant; DA: dopamine agonist; IGF1: Insulin-like Growth Factor 1; P: P-values 763 
when comparing the three subgroups of patients and controls. *in diabetic patients  764 
 765 
Table 2. Clinical characteristics of prospective patients (N=6).  766 
PY: packyears; BMI: body mass index in kg/m2; BP: blood pressure; IGF1: Insulin-like 767 
Growth Factor 1; SSA: Somatostatin analogue; DA: dopamine agonist; RT: radiotherapy. HG: 768 
hypogonadism; HC: hypocortisolism; HP: hyperprolactinemia; MP: menopause; PM: 769 
postmenopausal.  770 
* SSA were discontinued due to pancreatic problems.  771 
 772 
Figure 1. Study overview. 773 
IGF1: Insulin-like Growth Factor 1; hsCRP: high sensitivity C-reactive protein; IL: interleukin; 774 
IL18BP: IL18 binding protein; VCAM1: vascular cell adhesion molecule 1; MMP2: matrix 775 
metalloproteinase 2; LPS: lipopolysaccharide; PHA: Phytohemagglutinin; IL: interleukin; 776 
TNFa: tumor necrosis factor alpha; Ra: Receptor antagonist; IFNg: interferon gamma.  777 
 778 
Figure 2: LPS-induced IL10 production (A) and leukocyte counts (C) in controls and 779 
subgroups of patients (left panel) and prospective LPS-induced IL10 production (B) and 780 
leukocyte counts (D) in 6 prospectively followed patients (right panel).  781 
LPS: lipopolysaccharide; IL10: interleukin 10. 782 
 783 
Figure 3: Circulating VCAM1 (A), E-selectin (C) and MMP2 (E) levels in controls and 784 
subgroups of patients (left panels) and prospective VCAM1 (B), E-selectin (D) and MMP2 785 
(F) levels in 6 prospectively followed patients (right panel).  786 
VCAM: vascular cell adhesion protein; MMP: metalloproteinase. 787 
 788 
31  
Figure 4: Circulating hsCRP (A), IL18 (C) and IL18BP (E) levels in controls and subgroups 789 
of patients (left panels) and prospective hsCRP (B), IL18 (D) and IL18BP (F) levels in 6 790 
prospectively followed patients (right panel).  791 
hsCRP: high sensitivity cell-reactive protein; IL18: interleukin 18; BP: binding protein. 792 
 793 
Figure 5: prospective vascular measurements. IMT (A), IMT/lumen (B), PWA (C) and PWV 794 
(D). 795 
PWA: pulse wave analysis; PWV: pulse wave velocity; IMT: intima-media thickness. 796 
 797 
Figure 6: prospective FMD analysis. For each patients (A-F; 1-6) FMD baseline diameter, 798 
FMD peak diameter, % FMD change and FMD/NTG ratio are depicted.  799 
FMD: flow-mediated dilatation; NTG: nitroglycerin-mediated dilatation 800 
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Number 56 74 35 12  
Sex (male, N) 24 (43%) 35 (47%) 16 (46) 7 (58) 0.8 
Age (years) 47.5 (15.3) 55.8 (11.2) 47 (11.5) 52 (11.7) 0.001 
Height (m) 1.74 (0.1) 1.74 (0.1) 1.74 (0.1) 1.74 (0.1) 1 
Smoker (y/n, %) 13 (23.2) 10 (13.5) 5 (14.3) 2 (16.7) 0.1 
Weight (kg) 77.7 (16.1) 85.8 (20.7) 95.2 (20.5) 84.4 (10.2) 0.001 
BMI (kg/m2) 26.3 (18.3-46) 27.5 (20-49.1) 31.7 (23-41.4) 27.8 (22.5-36.4) 0.001 
Waist-to-hip ratio  0.94 (0.7-1.06) 0.92 (0.76-1.16) 0.9 (0.82-1.04) 0.94 (0.83-0.96) 0.487 
Systolic BP (mmHg) 123.1 (14.42) 129 (16) 122.5 (16.6) 130.3 (16.2) 0.074 
Diastolic BP (mmHg) 74.9 (9) 80.9 (10.3) 77.7 (11.9) 84 (15.2) 0.006 
Heart rate (/min) 64 (44-80) 61 (44-78) 60 (56-72) 60 (62-80) 0.09 
Hypertension (y/n) 6 (10.7) 30 (40.5) 13 (37.1) 6 (50) <0.001 
Diabetes mellitus  0 7 9 2 0.001 
HbA1c (mmol/mol)* - 52 (42-58) 55 (40-86) 49.5 (49-50) 0.32 
Hormonal deficiency  2 (3.6) 28 (37.8) 20 (57.1) 4 (33.3) <0.001 
Hypothyroidism 2 (3.6) 20 (27) 15 (42.9) 1 (8.3) <0.001 
Hypogonadism 0 (0) 18 (24.3) 11 (31.4) 3 (25) <0.001 
Hypocortisolism 0 (0) 12 (16.2) 7 (20) 1 (8.3) 0.001 
Alcohol use (IU/week) 3 (0-20) 2 (0-21) 2.5 (0-21) 7 (1-20) 0.16 
Packyears 0 (0-37.5) 0.5 (0-48) 0 (0-76) 0 (0-40) 0.54 
Treatment       
RT 0 12 (16.2) 12 (34.3) 0 (0) <0.001 
Surgery 0 (0) 66 (89.2) 29 (82.9) 0 (0) <0.001 
Medication 0 (0) 40 (54.1) 27 (77.1) 0 (0) <0.001 
SSA 0 (0) 34 (45.9) 22 (64.7) 0 (0)  
PEGV 0 (0) 10 (13.5) 5 (14.3) 0 (0)  
DA 0 (0) 7 (9.5) 14 (40) 0 (0)  
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PY: packyears; BMI: body mass index in kg/m2; BP: blood pressure; IGF1: Insulin-like 815 
Growth Factor 1; SSA: Somatostatin analogue; DA: dopamine agonist; RT: radiotherapy. HG: 816 
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TABLE 2  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Sex  Male Female Female Female  Male  Male  









































































































































































HG, HP, HC 
HG, HP, HC 
None  
